https://www.yorku.ca/yfile/2021/01/12/schulich-research-suggests-biopharma-companies-spend-too-much-time-on-drug-discovery-projects/
A new study out of York University's Schulich School of Business shows that biopharma companies might be 'pulling the plug' too late on research and...
research suggestsschulichbiopharmacompaniesspend
https://www.biopharmadive.com/news/astellas-biotech-center-san-francisco-cell-gene-therapy/627912/
The pharma company plans to spend $70 million on the South San Francisco facility, which will house West Coast employees of Astellas Gene Therapies.
research unitsastellasbringoneroof
https://www.biopharmadive.com/news/sanofi-coronavirus-vaccine-barda/572449/
The French drugmaker joins J&J as the second large pharmaceutical company to begin development of a vaccine against the virus that's spread quickly across...
coronavirus vaccinesanofistartsworkbringing
https://www.biopharmadive.com/news/sanofi-kevzara-covid-19-end-research/584504/
Kevzara failed to shorten hospital stays among patients severely sick with COVID-19, study results showed, further dimming hopes that drugs similar to it could...
sanofiendsresearcharthritisdrug
https://www.biopharmadive.com/news/ngm-series-a-raise-column-group-aldafermin/721457/
The Series A round was led by healthcare investor The Column Group, which made the 17-year-old biotechnology company private earlier this year.
ngmprivateraisesredrawnresearch
https://www.prnewswire.com/news-releases/research-reports-on-biotech-equities----mast-therapeutics-array-biopharma-galena-biopharma-and-clovis-oncology-599326391.html
/PRNewswire/ -- Growing concerns that a victory by Democratic nominee Hillary Clinton in the presidential election will result in tighter regulations on...
research reportsarray biopharmabiotechequitiesmast